RASSF1A Inactivation Unleashes a Tumor Suppressor/Oncogene Cascade with Context-Dependent Consequences on Cell Cycle Progression.
AuthorsRam RR, Mendiratta S, Bodemann BO, Torres MJ, Eskiocak U, White MA,
Journal
PubMed ID24732797
'The RASSF1A gene is one of the most frequently inactivated genes in over 30 different types of cancers (H. Donninger, M. D. Vos, and G. J. Clark, J. Cell Sci. 120:3163-3172, 2007, http://dx.doi.org/10.1242/jcs.010389). Despite the prevalence of RASSF1A silencing in human cancer, the mechanism by which RASSF1A functions as a ... More
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.
AuthorsSu JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC
JournalCancer Res
PubMed ID21911455
Gene therapy trials in human breast, ovarian, and head and neck tumors indicate that adenovirus E1A can sensitize cancer cells to the cytotoxic effects of paclitaxel in vitro and in vivo. Resistance to paclitaxel has been reported to occur in cells expressing low levels of the Forkhead transcription factor FOXO3a. ... More